Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 6, 2017 – Endo announced the voluntary market withdrawal of Opana ER (oxymorphone hydrochloride) extended-release tablets.
Download PDF
Return to publications
